mass treatment with oral azithromycin — Competitive Intelligence Brief

mass treatment with oral azithromycin (mass treatment with oral azithromycin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic. Area: Infectious Disease / Public Health.

marketed Macrolide antibiotic Bacterial 50S ribosomal subunit Infectious Disease / Public Health Small molecule

Target snapshot

mass treatment with oral azithromycin (mass treatment with oral azithromycin) — University of California, San Francisco. Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and in mass treatment campaigns is used to reduce transmission of infectious diseases at the population level.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
mass treatment with oral azithromycin TARGET	mass treatment with oral azithromycin	University of California, San Francisco	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithropycin according to symptoms	Azithropycin according to symptoms	University Hospital, Montpellier	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
CLDM 1% gel	CLDM 1% gel	GlaxoSmithKline	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
AzaSite®	AzaSite®	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Retapamulin (Altabax)	Retapamulin (Altabax)	The University of Texas Health Science Center, Houston	marketed	Pleuromutilin antibiotic	Bacterial 50S ribosomal subunit
linezolid (Zyvox)	linezolid (Zyvox)	Pfizer	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Linezolid antimicrobial-lock solution	Linezolid antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic class)

1. Pfizer · 6 drugs in this class
2. Grünenthal GmbH · 4 drugs in this class
3. Merck Sharp & Dohme LLC · 3 drugs in this class
4. University of Taubate · 2 drugs in this class
5. Lihir Medical Centre · 2 drugs in this class
6. Thomas Jefferson University · 2 drugs in this class
7. Copenhagen Studies on Asthma in Childhood · 1 drug in this class
8. Ain Shams Maternity Hospital · 1 drug in this class
9. Celltrion · 1 drug in this class
10. London School of Hygiene and Tropical Medicine · 1 drug in this class